紫杉醇联合吡柔比星治疗晚期乳腺癌临床观察

目的观察紫杉醇联合吡柔比星(THP)治疗晚期乳腺癌患者的临床疗效和毒性反应。方法26例晚期乳腺癌患者采用THP 40 mg/m2,静注,d1;紫杉醇135 mg/m2,静滴3 h,d1。21 d为1个周期,连用2个周期以上评价疗效。结果26例患者中CR 4例(15.4%),PR 14例(53.8%),SD 7例(26.9%),PD 1例(3.8%),总有效率为69.2%(18/26)。主要不良反应为骨髓抑制和脱发。结论紫杉醇联合吡柔比星治疗晚期乳腺癌疗效较高,不良反应可耐受,是治疗晚期乳腺癌安全、有效的方案。

Combination of paclitaxel and pirarubicin in the treatment of patients with advanced breast cancer

Objective To investigate efficacy and toxicity of combination of paclitaxel and pirarubicin in treatment of advanced breast cancer.Methods Twenty-six patients with advanced breast cancer were treated with paclitaxel plus pirarubicin.Pirarubicin 40 mg/m2 iv,d1;paclitaxel 135 mg/m2 iv 3 h,d1;every 21 days constituted a cycle.Efficacy and toxicity were evaluated after 2cycles.Results Among the total 26 cases,there were CR 4(15.4%),PR 14(53.8%),SD 7(26.9%),PD 1(3.8%),with an overall response rate(CR PR)of 69.2%(18/26).The main toxic reactions were myelosuppression and alopecia.Conclusion The combination of paclitaxel and pirarubicin can achieve a high response rate with toxicity tolerable by patients with advanced breast cancer.